Nonalcoholic fatty liver disease is the most common disorder in industrialized countries and link with metabolic risk factors such as diabetes, dyslipidemia, obesity, and metabolic syndrome. Recently a consensus of international experts redefined NAFLD to MAFLD (metabolic dysfunction associated with liver disease) which can more accurately reflect the pathogenesis and also help in the stratification of management.

Growing evidence suggests that NAFLD contributes to adverse liver outcomes such as HCC, and extrahepatic complications, but no more is known with the new definition. The progression of MAFLD is driven by hepatic inflammation and fibrogenesis and this could provide a reasonable rationale for new treatments.

This research topic aims at discussing the current debate on renaming NAFLD to MAFLD and the implications of changing terminology and summarizing the current state of knowledge regarding MAFLD.

Themes of interest include, but are not limited to:

• Differences in terminology between NAFLD and MAFLD;

• To rename NAFLD or not to rename?

• Implications of the change in terminology from NAFLD to MAFLD;

• The mechanisms underlying the pathophysiology of MAFLD;

• The role of enteroendocrine hormones in NAFLD;

• Differential role of enteroendocrine receptors in NAFLD;

• Targeting the gut microbiota in NAFLD;

• NAFLD vs MAFLD: should we care?

• Epidemiology and disease burden of MAFLD;

• Outcomes of MAFLD and differences from NAFLD;

• Epigenetic and microbiome aspects involved in MAFLD;

• Diagnosis and management of MAFLD and differences from NAFLD;

• Comparing and contrasting NAFLD and MAFLD;

• MAFLD: the views from scientific societies, healthcare providers, patients, and general public;

• Perspectives on MAFLD in different countries around the world;

• Special considerations in NAFLD and MAFLD;

• Differences in approaching MAFLD and NAFLD;

• Roles of lifestyle modification in the management of NAFLD and MAFLD;

• What interdisciplinary collaboration means for managing NAFLD and MAFLD;

• The challenges of drug therapy and liver transplant;

• Pharmacologic therapies for MAFLD;

• MAFLD and HCC: epidemiology and treatment approach.

Submit your idea

Impact

Frontiers in Endocrinology

Impact